Rating Change
Guggenheim analysts initiated coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a rating of Buy on October 06, 2026.
new coverageNASDAQ:OVID
Guggenheim Initiates Coverage on Ovid Therapeutics Inc. (OVID) with Buy
Guggenheim analysts initiated coverage on Ovid Therapeutics Inc. (NASDAQ:OVID) with a rating of Buy on October 06, 2026.
At publication ·
What changed
Ovid Therapeutics Inc. (NASDAQ:OVID) · new coverage
- Firm
- Guggenheim
- Rating
- Buy
- Price at event
- $2.37
- Market capitalization
- $117.3M
At a glance
Key takeaways
- Guggenheim initiated Buy coverage on Ovid Therapeutics (OVID) on October 6, 2026, as the healthcare stock trades at $2.37 with a $117.3 million market cap.
Market Context
Ovid Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $2.37 with a market capitalization of $117.3M. The stock has gained 42.7% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ovid Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ovid Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 06, 2026 | Guggenheim | Buy | N/A |
| Oct 05, 2026 | Guggenheim | Buy | N/A |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 03, 2026 | Oppenheimer | Outperform | N/A |
| Apr 15, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View OVID Stock Page
Frequently Asked Questions
What does the Buy rating mean for OVID?
A rating of Buy from Guggenheim reflects the analyst's outlook on Ovid Therapeutics Inc. (NASDAQ:OVID). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the OVID forecast page.